Bank Of America Corp Chimerix Inc Transaction History

Bank Of America Corp

$1.12 Trillion
Q2 2024

A detailed history of Bank Of America Corp transactions in Chimerix Inc stock. As of the latest transaction made, Bank Of America Corp holds 13,095 shares of CMRX stock, worth $11,261. This represents 0.0% of its overall portfolio holdings.

Number of Shares

13,095

Previous 13,045 0.38%

Holding current value

$11,261

Previous $13,000 15.38%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.87 - $1.05 $43 - $52	50 Added 0.38%	13,095 $11,000
Q1 2024 May 15, 2024	SELL	$0.91 - $1.26 $45 - $63	-50 Reduced 0.38%	13,045 $13,000
Q4 2023 Feb 14, 2024	SELL	$0.9 - $1.06 $330,577 - $389,346	-367,308 Reduced 96.56%	13,095 $12,000
Q2 2023 Aug 14, 2023	SELL	$1.1 - $1.54 $195,043 - $273,060	-177,312 Reduced 31.79%	380,403 $460,000
Q1 2023 May 12, 2023	SELL	$1.19 - $2.09 $9,828 - $17,261	-8,259 Reduced 1.46%	557,715 $702,000
Q4 2022 Feb 10, 2023	BUY	$1.67 - $2.35 $380,768 - $535,811	228,005 Added 67.46%	565,974 $1.05 Million
Q3 2022 Nov 14, 2022	BUY	$1.81 - $2.76 $550,373 - $839,244	304,074 Added 897.11%	337,969 $652,000
Q2 2022 Aug 12, 2022	SELL	$1.34 - $5.34 $160,247 - $638,599	-119,588 Reduced 77.92%	33,895 $70,000
Q1 2022 May 16, 2022	BUY	$4.58 - $6.8 $289,025 - $429,120	63,106 Added 69.83%	153,483 $703,000
Q4 2021 Feb 08, 2022	BUY	$5.23 - $7.18 $345,509 - $474,332	66,063 Added 271.71%	90,377 $581,000
Q3 2021 Nov 15, 2021	SELL	$5.94 - $8.75 $68,909 - $101,508	-11,601 Reduced 32.3%	24,314 $150,000
Q2 2021 Sep 13, 2021	BUY	$7.54 - $9.79 $270,799 - $351,607	35,915 New	35,915 $288,000

Others Institutions Holding CMRX

# of Institutions

Shares Held

36.8M

Call Options Held

72.2K

Put Options Held

169K

View Full List

About CHIMERIX INC

Ticker CMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,622,896
Market Cap $75.4M
Description
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...

More about CMRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Chimerix Inc Transaction History